Avacta Group PLC (LSE:AVCT) — Market Cap & Net Worth
Market Cap & Net Worth: Avacta Group PLC (AVCT)
Avacta Group PLC (LSE:AVCT) has a market capitalization of $3.91 Million (GBX32.17 Billion) as of June 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #29015 globally and #528 in its home market, demonstrating a 7.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avacta Group PLC's stock price GBX73.50 by its total outstanding shares 437633189 (437.63 Million). Review Avacta Group PLC (AVCT) total liabilities to assess the company's total debt and financial obligations.
Avacta Group PLC Market Cap History: 2015 to 2026
Avacta Group PLC's market capitalization history from 2015 to 2026. Data shows change from $7.16 Million to $3.91 Million (-5.89% CAGR).
Index Memberships
Avacta Group PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$939.61 Million | 0.42% | #48 of 722 |
Weight: Avacta Group PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Avacta Group PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avacta Group PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
23.56x
Avacta Group PLC's market cap is 23.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $7.16 Million | $1.81 Million | -$10.14 Million | 3.95x | N/A |
| 2016 | $3.83 Million | $2.17 Million | -$4.65 Million | 1.77x | N/A |
| 2017 | $3.41 Million | $2.73 Million | -$6.37 Million | 1.25x | N/A |
| 2018 | $1.62 Million | $2.76 Million | -$8.83 Million | 0.59x | N/A |
| 2019 | $918.21K | $3.89 Million | -$11.02 Million | 0.24x | N/A |
| 2020 | $6.07 Million | $2.14 Million | -$18.89 Million | 2.83x | N/A |
| 2021 | $6.71 Million | $2.94 Million | -$26.32 Million | 2.28x | N/A |
| 2022 | $6.12 Million | $9.65 Million | -$36.94 Million | 0.63x | N/A |
| 2023 | $6.20 Million | $2.85 Million | -$24.95 Million | 2.18x | N/A |
| 2024 | $2.66 Million | $113.00K | -$52.84 Million | 23.56x | N/A |
Competitor Companies of AVCT by Market Capitalization
Companies near Avacta Group PLC in the global market cap rankings as of June 19, 2026.
Key companies related to Avacta Group PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Avacta Group PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Avacta Group PLC's market cap moved from $7.16 Million to $ 3.91 Million, with a yearly change of -5.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX3.91 Million | +26.72% |
| 2025 | GBX3.09 Million | +16.00% |
| 2024 | GBX2.66 Million | -57.08% |
| 2023 | GBX6.20 Million | +1.30% |
| 2022 | GBX6.12 Million | -8.70% |
| 2021 | GBX6.71 Million | +10.53% |
| 2020 | GBX6.07 Million | +560.87% |
| 2019 | GBX918.21K | -43.44% |
| 2018 | GBX1.62 Million | -52.34% |
| 2017 | GBX3.41 Million | -11.11% |
| 2016 | GBX3.83 Million | -46.47% |
| 2015 | GBX7.16 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Avacta Group PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.91 Million USD |
| MoneyControl | $3.91 Million USD |
| MarketWatch | $3.91 Million USD |
| marketcap.company | $3.91 Million USD |
| Reuters | $3.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more